NEUROBIOLOGICAL TECHNOLOGIES, FDA AGREE ON TRIAL DESIGN FOR STROKE DRUG

Neurobiological Technologies has reached an agreement with the FDA on the design of its Phase III clinical trial for Viprinex. The FDA previously granted fast-track status to the overall Ancrod development program for acute ischemic stroke and now has additionally confirmed fast-track status for the clinical protocol.

Patient enrollment is expected to begin within the next few weeks, the company said Details of the trial will be made available upon initiation of the study.